Book a Meeting

Non-Fucosylated Anti-Human CD34 (9C5) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-661ZP) Datasheet

Target
CD34
Isotype
Humanized IgG1
Description
ADCC-Enhanced anti-CD34 (9C5 ) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform. By reducing the fucosylation of the Fc region, the ADCC-enhanced antibody shows an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Hematologic Malignancies; Solid Tumors
Classification
Therapeutic antibody; biobetter
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD34
Full Name
CD34 molecule
Background
The protein encoded by this gene may play a role in the attachment of stem cells to the bone marrow extracellular matrix or to stromal cells. This single-pass membrane protein is highly glycosylated and phosphorylated by protein kinase C. Two transcript variants encoding different isoforms have been found for this gene.
Alternative Names
CD34; CD34 molecule; hematopoietic progenitor cell antigen CD34; CD34 antigen
Gene ID
UniProt ID
Cellular Localization
Membrane
HGNC
OMIM
Involvement in Disease
Diseases associated with CD34 include Dermatofibrosarcoma Protuberans and Spindle Cell Lipoma.
Related Pathways
Its related pathways are C-MYB transcription factor network and Hematopoietic cell lineage.
Function
By mediating stem cells to attach to the extra-marrow matrix or directly attach to stromal cells, adhesion molecules that may play a role in the early hematopoietic process. It can be used as a scaffold for cell line-specific polysaccharides to bind stem cells to lectins expressed by stromal cells or other bone marrow components. Provide carbohydrate ligands for selection.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Controls and Markers antibody; Developmental Biology antibody; Immune System antibody; Neuroscience antibody; Pro-B Cell Marker antibody; Endothelial Cell Marker antibody; Angiogenesis Study antibody
Post-translational modifications
Highly glycosylated. Phosphorylated on serine residues by PKC.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Humanized IgG1
Antibody Clone
9C5
Host
Humanized
Species Reactivity
Human
Description
The anti-CD34 antibody that recognize the CD34 membrane-protein in the cell membrane, can be used in the clinical treatment of hematologic malignancies and solid tumors, hematopoietic stem / progenitor cells transplantation.
Indication
Hematologic Malignancies; Solid Tumors

Hematologic Malignancies; Solid Tumors

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK